{"nct_id":"NCT00489970","title":"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9","status":"COMPLETED","status_verified_date":"2020-04","start_date":"2007-06-01","start_date_type":"ACTUAL","primary_completion_date":"2011-09-01","primary_completion_date_type":"ACTUAL","completion_date":"2016-03-01","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GSK"]}